ArticleTranslational andrology and urology2025
Migrasome-related lncRNAs predict prognosis and immune response of clear cell renal cell carcinoma.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Migrasome-related long non-coding RNAs orchestrate immune microenvironment and serve as a novel prognostic model in clear cell renal cell carcinoma.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive renal malignancy. Migrasomes, newly discovered organelles involved in intercellular communication, and long non-coding RNAs (lncRNAs) are emerging regulators of cancer progression. However, the role of migrasome-associated lncRNAs in ccRCC prognosis and immune response remains unclear. This study aimed to investigate the value of migrasome-related lncRNAs and develop a risk model for ccRCC. Methods: By employing data from The Cancer Genome Atlas, we were able to identify prognostically significant migrasome-related lncRNAs through co-expression analysis, Cox regression, and least absolute shrinkage and selection operator (LASSO) regression. Prognostic models were developed and validated using these lncRNAs, and a nomogram combining the risk score with clinical features was constructed. Furthermore, our analyses encompassed gene set enrichment, immune infiltration, mutational burden, and drug sensitivity. Results: A prognostic model incorporating 13 lncRNAs effectively stratified patients into distinct risk categories, with the high-risk cohort demonstrating markedly inferior survival rates. The prognostic accuracy was validated through multiple analyses. Gene enrichment analysis revealed a correlation between these lncRNAs and tumor development and immune pathways. High-risk patients exhibited increased immunosuppressive cell infiltration, oncogenic mutations, and potential for immune escape. Furthermore, they demonstrated a lack of response to immunotherapy and exhibited differential responses to antineoplastic agents when compared to low-risk patients. We propose a prognostic model for ccRCC based on migrasome-related lncRNAs, providing new insights into disease progression and potential individualized treatment strategies. Conclusions: Our study proposes a prognostic model for ccRCC based on migrasome-related lncRNAs, providing new insights into disease progression and potential individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.